Introduction
It is well established that carcinogenic polycyclic aromatic hydrocarbons (PAHs*) covalently bind to DNA in vivo with the formation of characteristic profiles of DNA adducts (1, 2) . If these adducts are not repaired, or if repair introduces errors into the DNA sequence, gene mutations can be introduced upon replication of the damaged DNA. Certain mutations, particularly those resulting in activation of proto-oncogenes or inactivation of tumor suppressor genes, are thought to play a critical role in the carcinogenic process (3, 4) . Therefore, DNA adduct formation and persistence have been hypothesized to correlate with tumor formation in chemical carcinogenesis (5) . As DNA adduction by genotoxicants appears to be directly relevant to potential tumor formation, levels of DNA adducts may be useful as measures of the biologically effective dose of a carcinogen. Following chronic carcinogen administration, correlations have been made between steady-state DNA adduct levels and cancer incidence for a variety of chemicals (6) . However, relating DNA adduct levels to tumorigenesis following acute dosing is more challenging, since adduct levels change as a function of time after carcinogen treatment (7) (8) (9) and may follow different kinetics for different chemicals.
Most previous investigations on the molecular mechanisms by which PAHs elicit their biological activities, e.g. metabolic activation (10, 11) , DNA adduction (12, 13) and induction of mutations (14, 15) , have been performed with tetra-and pentacyclic PAHs, in particular with the prototype carcinogen benzo[a]pyrene (B[a]P) (16) . In contrast, much less is known of the biological effects of PAHs with six aromatic rings, although several members of this large group of PAHs, like the dibenzopyrenes, show significant carcinogenic activities (17) .
Recently, dibenzo[a,l]pyrene (DB[a,l]P) has been demonstrated to be highly mutagenic in the metabolically competent MCL-5 cell line derived from human B-lymphoblastoid cells (18) . In the human mammary carcinoma cell line MCF-7, DB[a,l]P is activated to fjord-region anti-and syn-11,12-dihydroxy-13,14-epoxy-11,12,13,14-tetrahydrodibenzo[a,l]-pyrene (DB[a,l]PDE) (19) . Another study has shown extensive binding of this metabolite to deoxyadenosine (dAdo) residues in DNA of the same cell line (20) . The reported total DNA binding potency of DB[a,l]P in mouse skin (21) was in accord with the exceptionally high carcinogenic activity observed in rodent bioassays (22) (23) (24) (25) . DB[a,l]P was a significantly more potent carcinogen than 7,12-dimethylbenz[a]anthracene (DMBA), or B[a]P in inducing tumors in rat mammary gland (22, 23) . In both initiation-promotion and repeated-application studies in mouse skin, at dose levels as low as 0.25 nmol, the carcinogenic potency of DB[a,l]P was much stronger than that of B[a]P or DMBA (24, 25) . DB[a,l]P has been detected in several environmental soil and sediment samples (26) , in cigarette smoke condensate (27) and in particulate matter formed during combustion of smoky coal (28, 29) . The extreme toxicity and carcinogenicity of DB[a,l]P (22) , accompanied by its prevalence in the environment, may pose a potential health risk to humans. To date, DB[a,l]P has not been evaluated for its carcinogenic efficacy in mouse lung, the relevant target organ for PAH-induced carcinogenesis in humans.
In this study, DB[a,l]P was examined for DNA adduction, tumorigenicity, and ability to induce Ki-ras oncogene mutations in tumors from the lungs of strain A/J mice following a single i.p. injection. The carcinogenic potency of DB[a,l]P was also evaluated in the light of our previously reported studies of environmental PAHs (9) that display a range of carcinogenic potencies in the strain A/J mouse lung tumor model. Our findings suggest that there exists a relationship between the specific DNA adducts formed, induction of Ki-ras mutations, and the tumorigenic potential of DB[a,l]P in the lungs of strain A/J mice.
Materials and methods

Chemicals and reagents
All chemicals and reagents were of analytical or enzyme grade unless otherwise mentioned. Poly deoxyadenosine (dAdo) and poly deoxyguanosine (dGuo) were obtained from Pharmacia-PL Biochemicals (Piscataway, NJ). Tris(hydroxymethyl)aminomethane (Tris), sodium lauryl sulphate (SDS), Na 2 EDTA, spermine tetrahydrochloride, sodium chloride, lithium chloride, zinc chloride, calcium chloride, magnesium chloride, mono-and dibasicsodium phosphate, sodium acetate, sodium succinate, ammonium acetate, citric acid, ethyl alcohol, dithiothreitol (DTT), urea, tricaprylin (1,2,3-trioctanoylglycerol), proteinase K, RNase A, RNase T1, and micrococcal nuclease were purchased from Sigma Chemical Co. (St Louis, MO). Glacial acetic acid, hydrochloric acid, purified 90% formic acid, ammonium hydroxide, and lithium hydroxide were obtained from Fisher Scientific (Fairlawn, NJ). Spleen phosphodiesterase and nuclease P1 were from CalBiochem (La Jolla, CA). 3Ј-Phosphatase-free polynucleotide kinase (PNK) was bought from BoehringerMannheim Biochemicals (Indianapolis, IN). [γ-32 P]ATP (sp. act. Ͼ 3000 Ci/ mmol) was from Amersham Corp. (Arlington Heights, IL). PEI-cellulose, TLC plates were obtained from Macherey-Nagel, Germany through Alltech Associates, Inc. (Deerfield, IL). DB[a,l]P was purchased from Chemsyn Science Laboratories (Lenexa, KS).
Animals and dosing
Male strain A/J mice, 5 to 6 weeks old, were purchased from the Jackson Laboratory (Bar Harbor, ME). Animals were housed five/cage and were maintained at 22Ϯ2°C at 30-60% relative humidity with a 12 h light/dark cycle. Water and food (Wayne Rodent Chow) were provided ad libitum. Groups of mice, weighing~20 g each (70 animals/group) were given single i.p. injections of 0.3, 1.5, 3.0, or 6.0 mg/kg body wt DB[a,l]P as a uniform suspension in tricaprylin. Animals in control groups received tricaprylin alone. Animal weights were recorded prior to injection and at time of sacrifice.
Tissue collection for DNA adducts, tumors, and Ki-ras mutation analyses At 1, 2, 3, 5, 7, 10, 21, and 28 days after treatment, five mice from each dose level were killed by CO 2 asphyxiation, and the entire lungs were removed and immediately placed into liquid nitrogen. After freezing, the lungs were stored individually at Ϫ80°C until DB[a,l]P-DNA adducts analysis by 32 Ppostlabeling. The remaining animals were housed in isolation units and received food and water ad libitum.
At 8 months after treatment, the remaining 30-35 animals/dose group were killed by cervical dislocation, and their lungs removed and examined for the presence of adenomas. Surface tumors on half the lungs were counted by gross inspection and individual tumors with some surrounding lung tissue were excised and frozen in liquid nitrogen for subsequent analysis of mutations in the Ki-ras oncogene. The remaining lungs were fixed in 10% neutral buffered formalin and the surface adenomas were counted under a dissecting microscope as described previously (30) .
DNA isolation for DB[a,l]P-DNA adduct analyses
DNA was isolated from whole lung tissue of individual animals using a salt and spermine technique (31) . Briefly, lung tissue was homogenized in 3.0 ml of 10 mM Tris-HCl, 400 mM NaCl, 2 mM Na 2 EDTA, pH 8.2, using a Tissuemizer (Tekmar, Cincinnati, OH). To the tissue homogenate, 0.2 ml of 10% SDS and 0.5 ml of proteinase K solution (2 mg/ml proteinase K in 1%
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SDS and 2 mM Na 2 EDTA) was added and incubated at 37°C for 4 h in a shaking water bath. Following incubation, 1.5 ml of saturated NaCl solution was added to the incubation mixture, vortexed for 20 s and centrifuged at 17 000 g for 15 min at 4°C to pellet the protein. To the supernatant 2 vols of room temperature absolute ethanol was added to precipitate the buoyant DNA. Spooled DNA was dissolved in 0.5 ml of TE buffer (10 mM Tris-HCl, 0.2 mM EDTA, pH 7.5) at 37°C. To 0.5 ml of DNA solution, 36.25 µl of an RNase mixture (10 µl 10 mg/ml RNase A, 1.25 µl 5000 U/ml RNase T1, in 25 µl 1 M Tris-HCl, pH 7.4) was added and incubated at 37°C for 30 min. To the incubation mixture 11 µl of proteinase K (50 mg/ml) was added and further incubated at 37°C for 30 min. DNA was precipitated again from the incubation mixture by adding 50 µl of 100 mM spermine tetrahydrochloride in TE buffer and cooled on ice for 10 min. DNA was collected by centrifugation and extracted three times with 1 ml of spermine extraction buffer (0.3 M LiCl and 15 mM sodium citrate in 75% ethanol). Samples were chilled at Ϫ20°C for 2 h for the first extraction and 30 min for the remaining extractions to remove residual spermine from DNA. Following a wash with 90% ethanol, DNA was resuspended in 200 µl of TE buffer to which 0.1 ml of 5 M ammonium acetate and 0.4 ml of cold absolute ethanol was added and the samples were placed at Ϫ80°C for 30 min to precipitate the DNA. The DNA was washed twice with 70% ethanol and solubilized in 1 ml of TE buffer and was stored at Ϫ80°C until analysis. The concentration of DNA was determined spectrophotometrically at 260 nm, and A 260 :A 280 ratios were within the range of 1.8 to 1.85 for all DNA samples. DB[a,l]P-DNA adduct analysis by 32 P-postlabeling DNA (5 µg/adduct assay) was hydrolyzed to 3Ј-mononucleotides by digestion with micrococcal nuclease and spleen phosphodiesterase essentially as described by Gupta (32) . Adducts were pre-enriched by digestion with nuclease P1, as described by Reddy and Randerath (33) , and then labeled at the 5Ј position with 3Ј-phosphatase-free polynucleotide kinase and [γ-32 P]ATP at pH 7.5. Resolution of radiolabeled adduct nucleotide bisphosphates was carried out by anion-exchange TLC on 10ϫ10 cm PEI-cellulose plates as previously described (7) (8) (9) , with minor modification, using the following solvent system: solvent D1: 1.0 M sodium phosphate (pH 6.0), with overnight elution onto a 10 cm wick of Whatman 3MM chromatography filter paper, followed by a wash with H 2 O; solvent D2: 2.75 M ammonium formate (pH 3.5), eluted just to the origin; solvent D3: 4.5 M lithium formate, 7.0 M urea (pH 3.5), eluted onto a 3 cm filter paper wick; following wash with H 2 O, the plates were eluted with 0.5 M Tris-HCl (pH 8.0) up to the origin; solvent D4: 1.1 M lithium chloride, 0.5 M Tris-HCl, and 7.0 M urea (pH 8.0), eluted onto a 3 cm filter paper wick, followed by a wash with H 2 O; and solvent D5 was 1.0 M magnesium chloride with elution onto a 3 cm Whatman 3MM chromatography filter paper wick. Total nucleotides were determined essentially as described by Gupta (32) . Phosphor imaging of DNA adducts and total nucleotides separated on TLC plates was performed at room temperature using imaging screens from Molecular Dynamics (Sunnyvale, CA). The screens were flooded with fluorescent light using a Molecular Dynamics Image Eraser for 8 min just before imaging of samples to erase any residual images. After exposure to TLC plates, (DNA adduct samples overnight and normal nucleotides for 30 min), the screens were scanned using the PhosphorImager (Model 400E) from Molecular Dynamics. Software used to analyze the data was Image Quant TM (v. 3.1) from Molecular Dynamics in the volume integration mode. Each cassette also included a standard PEIcellulose TLC strip spotted with a series of aliquots of serial dilutions of a 32 P solution. After exposure, the standard spots were excised and their 32 P disintegrations/min (dpm) measured by liquid scintillation counting. The pixel volumes for the standard spots and their corresponding dpm were used to construct a standard curve for each cassette exposure. The pixel volumes for each adduct spot were then converted to dpm using this standard curve. Relative adduct labeling values were calculated via the total nucleotides (32) and then converted to amol adducts/µg DNA.
Modification of polydeoxynucleotides with DB[a,l]PDEs
Racemic anti-and syn-DB [a,l] PDEs have been synthesized as previously reported (34) and obtained as gifts from Dr Shantu Amin (American Health Foundation, Valhalla, NY). Racemates anti-and syn-DB[a,l]PDE (100 mg each) were reacted separately with poly dGuo and poly dAdo (500 mg each) respectively in 0.05 M Tris, pH 7.4 and a total volume of 1 ml. The diolepoxides were dissolved in dried tetrahydrofuran at a concentration of 2 mg/ ml. To remove unreacted tetrols, the DB[a,l]PDE adducts were extracted with 1 vol of water-saturated 1-butanol five times and with water-saturated 1:1 ethyl acetate:diethyl ether, three times. The DB[a,l]PDE modified polynucleotide was precipitated with 100% ethanol (twice the volume) and 5 M NaCl (1/10 total volume), and centrifuged at 17 000 g for 15 min. at 4°C. The adducted polynucleotide was then washed with 70% ethanol (1 vol), centrifuged at 17 000 g for 15 min at 4°C, dissolved in HPLC grade water and stored at Ϫ80°C until analysis of the adducts by 32 P-postlabeling as described above. 
Analyses of Ki-ras mutations in DB[a,l]P-induced lung adenomas
High molecular weight DNA was extracted from individual lung adenomas using proteinase K and salt precipitation, followed by chloroform or phenolchloroform extraction as previously described (35) . Stock solutions of tumor DNA were stored at Ϫ20°C until PCR amplification. Amplification for sequencing of Ki-ras exon 2 and for SSCP (single strand conformation polymorphism) of exons 1 and 2 were as previously described (36, 37) with the PCR products purified on a 1.5% agarose gel, bands excised, electroeluted, and concentrated with a Centricon 30s (Amicon, Inc., Beverly, MA). For sequencing of exon 1, a 229 bp region was amplified using a primer that had a biotinylated 5Ј-end. A single stranded PCR product was isolated using streptavidin-linked magnetic beads (Sigma Chemical Co.), followed by concentration using a Microcon 30s (Amicon). The 27mer primers were: K1UERI, 5Ј-AGGGAATTCCTTGTGTGAGACATGTTC-3Ј, and K1LBTN, 5Ј-AGGC-TGCAGCGTCCTTTACAAGCGCAC-3Ј. The non-biotinylated strand was used for sequencing as previously described (36, 37) .
Numerical analyses
The time-integrated DNA adduct levels (TIDAL) were calculated by numerically integrating the areas under adduct persistence curves extrapolated to 250 days for DB[a,l]P at each dose level as described previously (9) . This value represents in a single parameter the total effective molecular dose of PAH delivered to the lung DNA over the entire course of tumorigenesis.
Survival study
In a separate experiment male strain A/J mice, 5-to 6-weeks-old, received high concentrations of DB[a,l]P (5 animals/dose; 12, 18, or 24 mg/kg) as a single i.p. injection in tricaprylin for survival and loss in body wt studies. Animal weights were recorded prior to injection and at time of killing. At 8 months after treatment, the animals were killed, and their lungs removed and examined for the presence of adenomas.
Results
Optimization of TLC for resolution of DB[a,l]P-DNA adducts in strain A/J mouse lung
Resolution of DB[a,l]P-DNA adducts on 10ϫ10 cm PEIcellulose plates was performed using the 32 P-postlabeling technique as described by Gupta (32) using conventional multidirectional chromatography with a urea-based solvent system. Because the mobilities of several of the DNA adducts were similar or did not separate from the origin (Figure 1b) , the method was modified to include the use of a 3 cm wick of Whatman 3MM chromatography filter paper for D3 and D4 dimensions to enhance adduct resolution. Under optimized TLC conditions, DB[a,l]P showed a complex adduct pattern on PEI-cellulose plates. Adducts were adequately separated from the origin and showed 10 distinct spots (Figure 1c) . All adducts were numbered in Figure 1c , and those that had similar chromatographic mobilities were subsequently assigned the same number in each panel of each adducts figure. Tricaprylintreated control animals did not show any adducts (Figure 1a) . (Figure 2a and 2b) . The minor adduct spot 5 is currently unidentified (Figure 1c ). Adduct spot 6 (Figure 1c) , one of the major adducts in DB[a,l]P administered mouse lung, is derived from the reaction of anti-or syn-DB[a,l]PDE with poly dAdo as confirmed by cochromatography with standard adducts (Figure 2c and 2d) . Adduct spots 7 and 8 ( Figure 1c ) comigrated with the reaction products of anti-DB[a,l]PDE with poly dGuo as shown in Figure 2b . In contrast, adduct spots 9 and 10 (Table I) . Quantitative analyses of DB[a,l]P-DNA adducts, measured at the time point of maximum binding revealed that the major proportion of the total DNA adducts were bound to dAdo and dGuo in DNA of strain A/J mouse lung in the ratio of~1:1. Adduct 6 was the major adduct, representing 33-37% of the total adducts formed at all dose levels studied ( Table I) .
Pharmacokinetics of DB[a,l]P-DNA adducts in strain A/J mouse lung
Levels and persistence of DB[a,l]P-DNA adducts, as measured by 32 P-postlabeling with nuclease P1 enrichment in strain A/J mice lungs DNA isolated up to 28 days after the last treatment of different doses of DB[a,l]P, are shown in Figure 3 . Total DNA adducts reached maximal levels between 5 and 10 days after injection followed by a gradual decrease. Most DB[a,l]P-DNA adducts were detectable at all time points and dose levels studied. No significant changes in the ratios of individual adducts were observed between time points and dose levels studied. Tumor induction and time-integrated DNA adduct levels in strain A/J mouse lung DB[a,l]P was well tolerated by strain A/J mice at all dose levels tested, and there were no significant decreases in body wt associated with treatment compared to vehicle-treated mice. However, there was a mild increase in severity and incidence of hepatocellular necrosis and inflammation associated with DB[a,l]P-treatment, but with no dose-related effect. As shown in Table II , lung adenomas induced by DB[a,l]P were prominent, with 100% tumor incidence at doses of 3.0 mg/kg and higher. The incidence and multiplicity of tumors induced by DB[a,l]P increased with dose. At the highest dose (6.0 mg/ kg) the average number of adenomas/mouse was 16.13 Ϯ 7.26 (mean Ϯ SD). Tricaprylin-treated control animals did not exhibit any adducts in the lung DNA and had an average of 0.67 Ϯ 0.80 adenomas/mouse. Urethane treatment at 1000 mg/ kg, used as positive control, induced 31.4 Ϯ 8.94 adenomas/ mouse, which was comparable to previously reported values (9, 30) . Figure 4 illustrates the induction of lung adenomas in strain A/J mouse lung as a function of the administered dose of DB[a,l]P, together with the results of previously studied environmental PAHs for comparison (9) . In a separate experiment conducted, the animals dosed with high concentrations, ranging from 12-24 mg/kg body wt DB[a,l]P also survived until killing at 8 months of age. There were no significant decreases in body wt associated with 12 or 18-mg/kg body wt DB[a,l]P-treated groups compared to vehicle-treated mice. However, there was a 22% weight loss in the 24 mg/kg DB[a,l]P-treated group. The lung adenomas/mouse in this group averaged 36.67 Ϯ 10.64 (mean Ϯ SD, n ϭ5).
The TIDAL value for DB[a,l]P at each dose level was calculated as described previously (9) by numerically integrating the areas under the adduct persistence curves (Figure 3 Figure 6 ). Ki-ras mutation spectrum in DNA from lung adenomas A total of thirty seven pulmonary adenomas were analyzed for mutations in the Ki-ras oncogene in codon 12 of exon 1 and codon 61 of exon 2 by PCR amplification followed by direct DNA sequencing and SSCP analysis. Twenty tumors were from animals that received 6.0 mg/kg DB[a,l]P, 10 were from animals that received 3.0 mg/kg, 6 from animals that received 1.5 mg/kg, and 1 from an animal that received 0.3 mg/ kg DB[a,l]P. A total of eighteen of the thirty seven tumors examined exhibited mutations in exons 1 and 2 of the Ki-ras gene. Forty four percent of the tumors with Ki-ras mutations were mutated in codon 12. The remainder of the tumors had point mutations detected in codon 61. The most common codon 12 mutations in tumors associated with DB[a,l]P treatment were GGT→TGT (28% of total ki-ras mutations), GGT→GTT (11%), and GGT→CGT (6%) (Figure 7a ). The frequent codon 61 mutations were CAA→CTA (22% of total ki-ras mutations), CAA→CGA (17%), CAA→CAT (11%), and CAA→CAC (6%) (Figure 7b ). The distribution of these mutations is different from those seen in untreated animals from two previous studies (38, 39) ; mutations in nine spontaneous tumors were distributed as follows: codon 12, four GGT→GAT and two GGT→GTT; codon 61, one CAA→CTA and one CAA→CAC. 
Discussion
Prior studies in mouse skin and rat mammary gland have provided ample evidence that DB[a,l]P is more highly carcinogenic than B[a]P and DMBA in inducing tumors (22) (23) (24) (25) . Total DNA binding potency in mouse skin following topical application (21) and high mutagenicity of DB[a,l]P in Salmonella and MCL-5 human cell assays (18) are in concordance with the demonstrated potency of DB[a,l]P as a powerful animal carcinogen. The purpose of the present investigation was to examine DB[a,l]P for its tumorigenic activity, induction of Ki-ras oncogene mutations in tumor DNA, and its ability to form specific DNA adducts in the strain A/J mouse lung tumor model.
PAHs require metabolic activation to chemically reactive intermediates in order to induce carcinogenesis and other biological activities. Structure-activity relationship studies suggest that 'bay region diol-epoxides', in which the oxirane ring is located in the bay region, are ultimate carcinogens of many PAHs that bind to DNA (40 (15, (41) (42) (43) (44) (45) . Due to the asymmetric structure of DB[a,l]P, containing both a bay and a fjord region, three regioisomers of sterically congested diol-epoxides can be formed: a bay region 1,2-diol-3,4-epoxide, and two fjord region epoxides, 3,4-diol-1,2-epoxide and 11,12-diol-13,14-epoxide. Furthermore, these diol-epoxides can be produced metabolically in a variable ratio of syn-and anti-diastereoisomers.
The pattern of adducts formed in strain A/J mouse lung (Figure 1b (19, 20) . These findings, together with the known in vitro activation of DB[a,l]P to 8,9-and 11,12-diols in the presence of rat liver (49) , and mainly to 11,12-diol by human lung and liver microsomes (50) , suggest that metabolic activation of this PAH proceeds through formation of the 11,12-diol-13,14-epoxide in both humans and strain A/J mice.
Analysis of DNA adducts in strain A/J mouse lung revealed the presence of at least ten adduct spots as determined by 32 (51) . Extensive reaction of both dGuo and dAdo residues in DNA of mouse skin has also been observed with the stericallyhindered bay region diol-epoxides of the potent carcinogen DMBA (52) . A recent report (53) also suggests that B[g]C diol-epoxides react extensively with DNA in vitro, forming adducts with both adenine and guanine bases, similar to the reactivities of the B[c]PhDEs. Furthermore, it has been shown that B[g]C is metabolically activated in mouse skin to two fjord region diol-epoxides, the (-)-anti and (ϩ)-syn diol epoxides, and that each of these active metabolites is capable of forming DNA adducts with both guanine and adenine bases (54) . Collectively, these and related findings demonstrate that the diol epoxides of PAHs whose structures are distorted from planarity by a fjord region exhibit high reactivity with both dGuo and dAdo residues in DNA, a property generally linked to the high carcinogenic potency of these PAHs.
The major DNA adduct (Figure 1c ; spot 6) in the mouse lung, which accounted for 33% to 37% of the total adducts formed, was the result of reaction of anti-DB [a,l] PDE with dAdo residues in DNA at all dose levels studied (Table I) . It is of interest to note that anti-isomers of the bay-and fjordregion diol-epoxides formed in cells and tissues are often associated with the increased mutagenic and carcinogenic potency of PAHs. For example, the anti-isomers of the bay region diol-epoxides of B[a]P and chrysene, among others, are more highly tumorigenic in newborn mice (55, 56) than are the syn-isomers. Bioassays of fjord region diol-epoxides of B[c]Ph in newborn mice have demonstrated that the antiisomers are among the most tumorigenic diol-epoxides tested to date (42) . In a recent study in newborn mice, racemic anti-DB[a,l]PDE was strongly tumorigenic in inducing lung and liver tumors even at a total dose as low as 0.7 nmols (57) . In the present study racemic DB[a,l]PDEs, rather than individual enantiomers were used for adduct identification. The use of racemic mixtures may obscure some differential enantiomeric effects, as the absolute stereochemistry of a diol-epoxide is an important determinant of its biological activity (41, 51) . Extensive adduction of dAdo residues in DNA was also observed in cells and tissues treated with DMBA (58), another potent carcinogenic PAH. In addition, the highly carcinogenic B[c]Ph diol-epoxides react extensively with dAdo in DNA, both in solution and in tissues (51, 59) . DB[a,l]P shows a similar reactivity with dAdo in lung DNA of strain A/J mice, that we believe may be causally related to the high carcinogenic potency of this PAH.
When compared with a set of carcinogenic PAHs that we recently examined in strain A/J mice (9), DB[a,l]P elicited the strongest tumor response with respect to administered doses. We found DB[a,l]P Ͼ 5-MeC Ͼ CPP Ͼ B[a]P Ͼ B[b]F, as the relative order of tumorigenic potency (Figure 4) . However, when evaluated with respect to tumor response plotted against the level of DB[a,l]P-DNA adducts that accumulate over time, i.e. TIDAL, a different relationship emerges ( Figure 6 ). In terms of tumor incidence versus TIDAL values, DB[a,l]P induces lung tumors with approximately the same potency as previously studied environmental carcinogenic PAHs (9) . In the present study, the greater tumorigenic activity of DB[a,l]P in mouse lung as a function of the administered dose, compared with the other environmental PAHs, can largely be attributed to the greater DNA binding of DB[a,l]P rather than a greater tumorigenic potential of its adducts, because all these PAH exhibit similar tumorigenic potential when viewed in terms of TIDAL. The observed differences in the tumorigenic potencies of these PAHs as a function of the administered dose could be due to differences in their absorption, transport, metabolic activation, detoxification, and DNA repair, which are major determining factors for covalent modification or damage to target DNA.
The percentage of mutations seen in tumor DNA of codons 12 (44%) and 61 (56%) of Ki-ras oncogene (Figure 7) are consistent with the types of DNA adducts formed by DB[a,l]P in the lungs of strain A/J mice, with adducts at dGuo and dAdo residues in DNA formed in almost equal proportions 1961 (Table I) . DB[a,l]P induced Ki-ras oncogene mutations in a relatively lower proportion (49%) of adenomas compared to the much larger proportions (80-97%) induced by other lung carcinogens in strain A/J mice (9) . Similarly, DB[a,h]A is also an extremely potent lung carcinogen in strain A/J mice, but it does not induce detectable Ki-ras mutations in mouse lung tumors (9) , suggesting the existence of at least two pathways of tumorigenesis in strain A/J mouse lung.
In summary, we have demonstrated that DB[a,l]P is an extremely potent lung carcinogen with respect to administered dose, compared with other environmental PAHs that we have examined in strain A/J mouse. In terms of tumor incidence versus TIDAL, DB[a,l]P induced lung tumors with about the same potency as other carcinogenic PAHs showing that the adducts formed are similar in carcinogenic potency to other PAHs. We have also shown that DB[a,l]P is metabolically activated in mouse lung to both anti-and syn-DB [a,l] PDEs. Each of these active metabolites forms DNA adducts with both dGuo and dAdo residues in DNA, a characteristic previously associated with PAHs having potent carcinogenic activity in rodents. Furthermore, our data support a role of Ki-ras activation in lung tumors induced by DB[a,l]P, consistent with the formation of major DNA adducts in strain A/J mouse lung.
